Sitemap - 2021 - Boutique Biotech

Medicenna in the spotlight (part IV)

Affimed in the spotlight (part VII)

The Omicron variant

Affimed in the spotlight (part VI)

Eloxx Pharmaceuticals in the spotlight (part V)

Medicenna in the spotlight (part III)

Eloxx Pharmaceuticals in the spotlight (part IV)

Affimed in the spotlight (part V)

Affimed in the spotlight (part IV)

Medicenna in the spotlight (part II)

F-Star Therapeutics in the spotlight (part II)

Autolus Therapeutics and F-Star Therapeutics in the spotlight

$MDNA, $NMTR, and $ELOX

Affimed update

Medicenna in the spotlight

Fate Therapeutics in the spotlight

Novavax in the spotlight (part VII)

Assessing the Trillium takeout

Eloxx Pharmaceuticals in the spotlight (part III)

ESSA Pharma in the spotlight (part II)

ESSA Pharma in the spotlight

Jounce Therapeutics in the spotlight (part III)

Novavax in the spotlight (part VI)

Novavax in the spotlight (part V)

Magenta Therapeutics in the spotlight (part III)

Eloxx Pharmaceuticals in the spotlight (part II)

Affimed’s BCMA candidate

Jounce Therapeutics in the spotlight (part II)

Recursion Pharmaceuticals in the spotlight

Eloxx Pharmaceuticals in the spotlight

Verve Therapeutics in the spotlight

Jounce Therapeutics in the spotlight

Novavax in the spotlight (part IV --brief update)

Novavax in the spotlight (part III)

Biogen's aducanumab

$MGTA update from 2021 ASCO Annual Meeting

Genocea Biosciences

Magenta Therapeutics

Affimed (AFMD) analysis deep-dive

Novo Nordisk stock price action update

Novavax in the spotlight (part II)

Novavax in the spotlight

Is the Novo Nordisk stock price drop warranted?